AARHUS UNIVERSITY

Press release

Please fill in this form and return it to graduateschoolhealth@au.dk in Word format along with a portrait photo in JPEG format, if you would like it to accompany your press release, no later than three weeks prior to your defence.

Basic information

Name: Kirstine Petrea Bak-Fredslund Email: kbf@clin.au.dk Phone: 21689921

Department of: Clinical Medicine

Main supervisor: Susanne Keiding MD, DSc

Title of dissertation: 2-[18F]-fluoro-2-deoxy-D-galactose PET/CT in patients with hepatocellular carcinoma – methodological aspects and clinical impact

Date for defence: Friday August 24th at (time of day): 14:00 Place: Palle Juul-Jensen Auditorium, Aarhus University Hospital, Nørrebrogade 44, building 10G, Aarhus

Press release (Danish)

PET/CT med det radioaktivt mærkede sukkerstof FDGal kan have behandlingsmæssig betydning hos patienter med kræft udgående fra leverceller.

2-[18F]-fluoro-2-deoxy-D-galactose (FDGal) er et radioaktivt mærket sukkerstof som kan bruges til avanceret 3-dimensionel billedundersøgelse (PET/CT) af leverens funktion. I dette ph.d. projekt blev det søgt at forenkle metoden for FDGal PET/CT i mennesker samt undersøge udbyttet af at supplere det vanlige billeddiagnostiske udredningsprogram med FDGal PET/CT hos patienter med kræft udgående fra leverceller. Det blev fundet, at vurdering af leverfunktionen med FDGal PET/CT kan metodemæssigt forenkles og ikke viser større udsving ved gentagne skanninger hos raske og patienter med leversygdom i stabil fase. FDGal PET/CT hos patienter med kræft udgående fra leverceller førte hos 5 af de 50 undersøgte patienter til fund af hidtil uopdaget spredning udenfor leveren, som medførte ændret behandling. FDGal PET/CT kan overvejes hos patienter med kræft udgående fra leverceller, hvor afklaring af mulig spredning er særlig vigtig som f.eks. forud for lever transplantation. Sådan lyder nogle af konklusionerne i et nyt ph.d.-projekt fra Aarhus Universitet, Health. Projektet er gennemført af Kirstine Bak-Fredslund, der forsvarer det d. 24/08 2018

Forsvaret af ph.d.-projektet er offentligt og finder sted den 24/8 2018 kl. 14:00 i Palle Juul-Jensen Auditorium, Aarhus Universitetshospital, Nørrebrogade 44, bygning 10G, Aarhus. Titlen på projektet er "2-[18F]-fluoro-2-deoxy-D-galactose PET/CT in patients with hepatocellular carcinoma – methodological aspects and clinical impact". Yderligere oplysninger: Ph.d.-studerende Kirstine Petrea Bak-Fredslund, e-mail: kbf@clin.au.dk, tlf. 2168 9921.

Bedømmelsesudvalg:
Cai Grau, Professor, overlæge, dr. med., Kræftafdelingen, Aarhus Universitetshospital, Aarhus, Denmark. (formand)
Per Stål klinisk lektor, læge, Enheden for Hepatologi ved medicinsk afdeling, Karolinska Institut, Karolinska Universitets Hospital, Huddinge, Stockholm, Sverige.
Søren Møller Professor, læge, DSc, Klinisk Fysiologisk Sektion ved Funktions og Billeddiagnostisk Enhed, Københavns Universitet, Hvidovre Hospital, Denmark.

Press release (English)

PET/CT with the radioactively labelled sugar FDGal may have impact on choice of treatment in patients with primary liver cancer.

2-[18F]-fluoro-2-deoxy-D-galactose (FDGal) is a radioactively labelled sugar that can be used for sophisticated 3-dimensional imaging (PET/CT) of liver function. In this PhD study it was investigated whether the method for FDGal PET/CT in humans could be simplified along with an examination of

the potential benefits of adding FDGal PET/CT to the ordinary imaging work-up in patients with primary liver cancer. It was established that the evaluation of liver function with FDGal PET/CT could be simplified and that results from repeated examinations of healthy subjects and patients with stabile cirrhosis of the liver only showed minimal differences. In patients with primary liver cancer, FDGal PET/CT lead to a change in the choice of treatment in five of the 50 patients included in the study due to the findings of previously unknown metastases outside the liver. FDGal PET/CT may be considered for patients in whom clarification of potential spread of primary liver cancer outside the liver is paramount such as patients considered for liver transplantation. This is some of the conclusions of a new PhD project from Aarhus University, Health. The project was carried out by Kirstine Petrea Bak-Fredslund, who is defending her dissertation on 24/08 2018.

The defence is public and takes place on 24/08 2018 at 14:00 in Palle Juul-Jensen Auditorium, Aarhus University Hospital, Nørrebrogade 44, building 10G, Aarhus. The title of the project is "2-[18F]-fluoro-2-deoxy-D-galactose PET/CT in patients with hepatocellular carcinoma – methodological aspects and clinical impact". For more information, please contact PhD student Kirstine Petrea Bak-Fredslund, email: kbf@clin.au.dk, Phone +45 2168 9921.

Assessment committee:
Cai Grau, MD, DSc, Clinical Professor Department of Oncology Aarhus University Hospital, Aarhus, Denmark. (chairman)
Per Stål MD, Associate Professor Division of Hepatology, Department of Medicine, Center for Digestive Diseases, Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm, Sweden.
Søren Møller MD, DSc, Professor Department of Clinical Physiology and Nuclear Medicine Copenhagen University Hospital Hvidovre, Denmark

Permission

By sending in this form:

- I hereby grant permission to publish the above Danish and English press releases as well as any submitted photo.
- I confirm that I have been informed that any applicable inventions shall be treated confidentially and shall under no circumstances whatsoever be published, presented or mentioned prior to submission of a patent application, and that I have an obligation to inform my head of department and the university's Patents Committee if I believe I have made an invention in connection with my work. I also confirm that I am not aware that publication violates any other possible holders of a copyright.